PDOX News

Updates, happenings and news clips from the AntiCancer PDOX ecosystem. 

UCLA's Dr. Fritz Eilber discusses his work with sarcoma patients and highlights the urgency of finding the right treatment for each patient.

Two landmark studies are now underway to determine if treatment can benefit the patient after only one cycle.

Watch Here

April 5, 2017: Dr. Thinar Lwin of AntiCancer and the University of California at San Diego presents her poster at AACR this week.

The research demonstrates the efficacy of fluorescent imaging in tumor-specific antibody labeling of pancreatic cancer.

Learn More

April 2, 2017: Day One of the AACR Annual Meeting here in Washington, D.C.

Come visit the AntiCancer/PDOX team in Booth #2806 and meet Charlene Cooper, Dr. Robert Hoffman, and Peter Ellman.

Learn More

March 18, 2017: SSO 2017 Annual Cancer Symposium/Seattle

Session #70: Tumor Grade & Preoperative Therapy Impact the Establishment of Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): UCLA Sarcoma Program Prospective Clinical Trial”

By Dr. Tara Russell, M.D.
Research Fellow/Surgical Resident

UCLA Department of Surgical Oncology-1:30 p.m., Room 6A

Learn More

March 9, 2017: Cancer Forum/Musculoskeletal Research Group Tumor Board presentation at UCLA

“Tumor Grade & Neoadjuvant Therapy Impact The Establishment of Soft-Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX): A UCLA Sarcoma Program Prospective Clinical Trial”
By Tara Russell, M.D.

Learn More

March 1, 2017: Glowing Mouse Presentation and Talk/La Jolla, Calif.

For the 10th year, Dr. Robert Hoffman, founder of AntiCancer, Inc., presented to the students at La Jolla (Calif.) High School. Dr. Hoffman is in the back row toward the left. Dr. Ming Zhao and Dr. Makoto Toneri are in the front row to the right.

Learn More

January 27, 2017: Stepping up the war on cancer with new technology

From Emily Adam at Select Science
Stepping up the war on cancer with new technology: Learn how Dr. Robert Hoffman is shifting the paradigm in cancer research.

Learn More

November 9, 2016: Connective Tissue Oncology Society (CTOS), Lisbon, Portugal

“Factors Impacting the Establishment of Individual Soft Tissue Sarcoma Patient-Derived Orthotopic Xenografts (PDOX) Mouse Models: A UCLA Sarcoma Program Prospective Clinical Trial” by Eckardt et al.

By Tara Russell, MD, MPH
UCLA General Surgery Resident
This study demonstrates a very high (82%) establishment rate for PDOX in HG-STS patients who were treatment naïve at the time of surgical excision.

Learn More